T. Ram Reddy et al. / Bioorg. Med. Chem. Lett. 21 (2011) 6433–6439
6439
various Pd-mediated C–C bond forming reactions as demonstrated
above.
analytical group of DRL for spectral data. M.P., S.S. and P.M. thank
Professor Seyed E. Hasnain and Professor J. Iqbal for encourage-
ment and DBT, New Delhi, India for financial support (Grant No.
BT/01/COE/07/02). Technical help in pharmacology from Dr. K.
Chatti is acknowledged.
Some of the compounds synthesized were tested for CM inhibit-
ing properties in vitro and the results are summarized in Table 5.
The assay13 involved determination of activity of enzyme CM which
catalyzes the conversion of chorismate to prephenate. Thus deter-
mination of activity of CM is based on the direct observation of con-
version of chorismic acid to prephenate spectrophotometrically at
OD274. This reaction is performed in the presence of test compounds
to determine their CM inhibiting activities. A known inhibitor of CM
that is, 4-(3,5-dimethoxyphenethylamino)-3-nitro-5-sulfamoyl-
benzoic acid2a was prepared and used as a reference compound
Supplementary data
Supplementary data associated with this article can be found, in
the IC50 value of which was found to be less than 10
lM. While none
References and notes
of the compound 5 showed significant inhibition14 of CM at 50
lM
1. Haslam, E. Shikimic Acid: Metabolism and Metabolites; Wiley: New York, 1993.
2. For selected references, see: (a) Agarwal, H.; Kumar, A.; Bal, N. C.; Siddiqi, M. I.;
Arora, A. Bioorg. Med. Chem. Lett. 2007, 17, 3053; (b) Hediger, M. E. Bioorg. Med.
Chem. 2004, 12, 4995; (c) Bartlett, P. A.; Nakagawa, Y.; Johnson, C. R.; Reich, S.
H.; Luis, A. J. Org. Chem. 1988, 53, 3195.
3. Armstrong, R. W.; Combs, A. P.; Tempest, P. A.; Brown, S. D.; Keating, T. A. Acc.
Chem. Res. 1996, 29, 123.
4. For recent progress in the chemistry of multicomponent reactions, see: Ugi, I.
Pure Appl. Chem. 2001, 73, 187.
compounds 7 and 10 however showed moderate to good inhibition
at the same concentration depending on the nature of substituents
present. In general, alkyne substituted compounds for example, 10
was found to be superior than alkenyl derivatives 7. Among the al-
kyne derivatives a linear side chain attached to the triple bond usu-
ally showed good inhibitory activities and presence of a hydroxy
group at the end of the side chain was found to be beneficial. Nev-
ertheless, compound 10g and 10h was identified as best inhibitors
in this series. Compound 10g showed dose dependent inhibition of
5. Dömling, A. Curr. Opin. Chem. Biol. 2000, 4, 318.
6. (a) Merkul, E.; Boersch, C.; Frank, W.; Muller, T. J. J. Org. Lett. 2009, 11, 2269; (b)
Banfi, L.; Basso, A.; Cerulli, V.; Guanti, G.; Riva, R. J. Org. Chem. 2008, 73, 1608;
(c) Umkehrer, M.; Kalinski, C.; Kolb, J.; Burdack, C. Tetrahedron Lett. 2006, 47,
2391.
CM with an IC50 value 15.63 lM (Fig. 2).
To understand the nature of interactions between 10g and CM
docking studies were performed (Fig. 3) which showed H-bonding
interactions between (i) the –CN group of 10g and the ARG72 res-
idue of CM, (ii) the –OH group of 10g and ASN142 and LYS79 res-
idues of the CM. The overall binding energy was found to be
À5.5 kcal molÀ1 indicating significant interactions of 10g with CM.
In conclusion, systematically modified functionalized 2-amino-
chromenes has been prepared via a new strategy involving a MCR
and palladium catalyzed C–C bond forming reaction. This strategy
involves the use of bromobenzaldehyde as a key component and
afforded a new compound library based on 2-aminochromene
framework. Many of these compounds showed M. tuberculosis
H37Rv chorismate mutase inhibiting properties in vitro and the
7. Kidwai, M.; Saxena, S.; Khan, M. K. R.; Thukral, S. S. Bioorg. Med. Chem. Lett.
2005, 15, 4295.
8. Heravi, M. M.; Bakhtiari, K.; Zadsirjan, V.; Bamoharram, F. F.; Heravi, O. M.
Bioorg. Med. Chem. Lett. 2007, 17, 4262.
9. Elinson, M. N.; Ilovaisky, A. I.; Merkulova, V. M.; Belyakov, P. A.; Chizhov, A. O.;
Nikishin, G. I. Tetrahedron 2010, 66, 4043.
10. (a) Zhou, D.; Chen, R. Z. J.; Cao, W.; Deng, H. J. Heterocycl. Chem. 2009, 45, 1865;
(b) Shestopalov, A. M.; Emelianova, Y. M.; Nesterov, V. N. Russ. Chem. Bull., Int.
Ed. 2002, 51, 2238.
11. Elagamay, A. G. A.; El-Taweel, F. M. A. A. Indian J. Chem. B 1990, 29, 885.
12. The one-pot transformation was typically carried out as follows: a mixture of
1-naphthol 1 (10 mmol), malononitrile 2 (10 mmol) and bromo aldehyde 3
(10 mmol) in dioxane (5 mL) was cooled to 0–5 °C and then aryl boronic acid
(12.0 mmol), (PPh3)2PdCl2 (0.002 mmol) and pyrrolidine (5 mmol) was added
at 0–5 °C. The resulting mixture was stirred at 0–5 °C for 30 min and then at
70 °C for the duration as indicated in Table 2. The desired product 5 was
isolated after usual work-up (see the Supplementary data).
13. (a) Kim, S. K.; Reddy, S. K.; Nelson, B. C.; Vasquez, G. B.; Davis, A.; Howard, A. J.;
Patterson, S.; Gilliland, G. L.; Ladner, J. E.; Reddy, P. T. J. Bacteriol. 2006, 188,
8638; (b) Sasso, S.; Ramakrishnan, C.; Gamper, M.; Hilvert, D.; Kast, P. FEBS J.
2005, 272, 375.
IC50 value of one compound was found to be 15.63 lM. Overall,
2-aminochromene framework has been identified as a new tem-
plate for the design and discovery of small-molecule based inhibi-
tors of CM for the potential treatment of tuberculosis.
14. Precipitation of the compound 5 observed in most of the cases in assay
medium.
Acknowledgments
The authors (T.R.R., L.S.R., N.V.S. and G.R.R.) thank Dr. Vilas
Dahanukar and Dr. Amrendra Kumar Roy for support and the